← All trials
NCT04826094
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 16, 2021
- Primary completion
- Feb 8, 2023
- Completion date
- Feb 8, 2023
- First posted
- Apr 1, 2021
- Last posted
- Apr 1, 2021
- Enrollment
- 126
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- United States ArmyStudy chair
- United States ArmyCollaborator
- United States ArmyCollaborator
- The EMMES CorporationCollaborator
- United States ArmyCollaborator
- Kenya Medical Research InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.